News & Media

Case Report Featured in Faculty Opinions

See the Faculty Opinions and Recommendations featured in Faculty Opinions HERE Our work was was also featured in Faculty Opinions Blog — such a great piece with wonderful interviews with Barbara Scolnick MD and Caroline! Jump in and read it HERE Read our full case report in Frontiers in Psychiatry HERE

Continue Reading

Remission from Chronic Anorexia Nervosa With Ketogenic Diet and Ketamine: Case Report

1Internal Medicine & Addiction Medicine, Waban, MA, United States 2Consultant-Ketogenic Diet Therapy LLC, Elm Grove, WI, United States 3Innovative Psychiatry, South Windsor, CT, United States 4Center for Neural Sciences, New York University, New York, NY, United States 5The Neuroscience Institute, NYU Langone Medical Center, New York, NY, United States 6Center of Excellence in Eating and Weight […]

Continue Reading

A look at a potential treatment for Chronic Anorexia Nervosa

By Hannah Towfiq 5 February 2021 Anorexia Nervosa is an eating disorder that can affect people of all ages, genders, sexual orientations, races, and ethnicities. It is characterized by extreme weight loss and consequent difficulties maintaining an appropriate body weight for the height and age of the sufferer. It is not a new condition, and many historians […]

Continue Reading

The Ketamine Conference: A Molecular Masterclass

Molecular Masterclass Ketamine Conference presented by Jeffrey Becker, M.D.

The Ketamine Conference: A Molecular Masterclass is set to take place today, featuring a host of experts in the delivery of ketamine therapy for resistant conditions such as PTSD, depression, and anxiety. Presented by Bexson Biomedical, The Conscious Fund, and Microdose, it will bring together leaders in the field of ketamine science and delivery, and will translate the […]

Continue Reading

The Next Covid Crisis Could Be a Wave of Suicides

Isolation and anxiety are a recipe for substance abuse and mental illness. A new study predicts 75,000 “deaths of despair.” By Cynthia Koons, Riley Griffin, and Emma Court May 7, 2020, 9:14 PM PDT The isolation, grief and economic hardship related to Covid-19 are creating a mental health crisis in the U.S. that researchers warn could make the already-rising suicide […]

Continue Reading

Ketamine’s promise as an antidepressant is being undermined by its lack of profit

Esketamine, the first new method to treat depression in 25 years, isgaining credibility. Last year, Janssen Pharmaceutical’s ketaminebaseddrug was approved by the US Food and Drug Administration(FDA) to treat patients with treatment-resistant depression. And onAug. 3, the FDA followed up with a second approval, allowing doctorsto prescribe the tranquilizing drug to patients experiencing suicidalideation. But […]

Continue Reading

Suicide Mortality and Coronavirus Disease 2019: A Perfect Storm?

Mark A. Reger, PhD1,2;  Ian H. Stanley, MS1,3;  Thomas E. Joiner, PhD3 Author Affiliations: Article Information JAMA Psychiatry. Published online April 10, 2020. doi:10.1001/jamapsychiatry.2020.1060 Suicide rates have been rising in the US over the last 2 decades. The latest data available (2018) show the highest age-adjusted suicide rate in the US since 1941.1 It is within this context that coronavirus disease 2019 (COVID-19) […]

Continue Reading

Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected

FDA approves Spravato, a version of ketamine backed by Johnson & Johnson that sees rapid results in patients battling treatment resistant depression and suicide. HOUSTON, March 5, 2019 /PRNewswire/ — “New FDA approved depression treatment, esketamine, is the biggest advancement in depression treatment in thirty years” – says Houston based Psychiatrist, Dr. Sandhya Prashad. This approval allows ketamine treatments to be […]

Continue Reading